



California State Board of Pharmacy

1625 N. Market Blvd, N219, Sacramento, CA 95834
Phone: (916) 574-7900
Fax: (916) 574-8618
www.pharmacy.ca.gov

STATE AND CONSUMER SERVICES AGENCY
DEPARTMENT OF CONSUMER AFFAIRS
GOVERNOR EDMUND G. BROWN JR.

NOTICE OF MEETING AND AGENDA
California State Board of Pharmacy
LEGISLATION AND REGULATION COMMITTEE
April 24, 2012

Contact Person: Virginia Herold
(916) 574-7911

DATE: April 24, 2012

PLACE: NOTE LOCATION OF MEETING
Department of Consumer Affairs
~~Headquarters Building II~~
~~1747 North Market Blvd., Room 186~~
Sacramento, CA 95834

CORRECT LOCATION:
1625 N. Market Blvd.
1ST Floor Hearing Room

This committee meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Richard Hultgren at (916) 574-7934, by emailing richard.hultgren@dca.ca.gov or sending a written request to the Board of Pharmacy, 1625 N. Market Blvd., Suite N-219, Sacramento, CA 95834. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.

Opportunities are provided to the public to address the committee on each open agenda item. Board members who are not on the committee may attend the meeting as observers. Action may be taken on any item on the agenda.

CONTINUING EDUCATION: Pharmacists and pharmacy technicians who attend the full committee meeting in person may be awarded two hours of Continuing Education (CE) in accordance with the Board's CE policy. Sign-in and sign-out that day is required for the CE credit.

Agenda

Call to Order

9:00 a.m.

A. LEGISLATION REPORT

1. Legislation Impacting the Practice of Pharmacy or the Board's Jurisdiction

a. Regulation of Dangerous Drugs and Devices

- SB 1329 (Simitian) Prescription Drugs: Collection and Distribution Program
- SB 419 (Simitian) Solid Waste: Home Generated Sharps
- SB 1301 (Hernandez) Prescription Drugs: 90-Day Supply

- AB 389 (Mitchell) Bleeding Disorders: Blood Clotting Products
- AB 1442 (Wieckowski) Common Carriers to Transport Pharmaceutical Waste
- AB 2369 (Valadao) Prisoners: Pharmacy Services
- AB 2348 (Mitchell) Registered Nurses: Dispensing Oral Contraception in Clinics

b. Sunset Review and Legislative Oversight

- SB 1237 (Price) Sunset Extension to 2017

c. Licensing and Pharmacy Operations

- SB 1095 (Rubio) Pharmacy: Surgical Clinics
- SB 1481 (Negrete McLeod) Clinical Laboratories: Community Pharmacies
- AB 377 (Solorio) Hospital Central Fill Pharmacies
- AB 1896 (Chesbro) Tribal Health Programs: Health Care Practitioners
- AB 1904 (Block) Military Spouses: Temporary License

d. Other

- SB 1185 (Price) Centralized Intelligence Partnership Act (DCA)
- SB 1195 (Price) Public Records Act
- SB 1250 (Alquist) Medical Records: Confidentiality
- AB 2342 (Torres) Controlled Substances
- AB 1733 (Logue) Telehealth

2. Board-Sponsored Legislation for 2012

SB 1575 (Senate Committee on Business, Professions and Economic Development) Omnibus

3. Additional Legislation Impacting the Board or Its Regulatory Jurisdiction

B. REGULATION REPORT

1. Board Approved – Undergoing Review by the Administration

- a. Add Title 16 Section 1727.2 – Requirements for Pharmacist Interns – To Require Applicants to Submit a Self-Query from the National Practitioner Data Bank – Healthcare Integrity & Protection Data Bank (NPDB-HIPDB)

[45-day comment period: May 6-June 20, 2011. Pending Review at Department of Finance.]

- b. Amend Title 16 Section 1728 – Requirements for Pharmacist Examination - Amend to Require Applicants to Submit a Self-Query from the National Practitioner Data Bank – Healthcare Integrity & Protection Data Bank (NPDB-HIPDB)

[45-day comment period: May 6-June 20, 2011. Pending Review at Department of Finance.]

2. Possible Action – Board-Approved Regulations Recently Noticed

Review of Comments Submitted During 45-day Comment Period – Proposed Amendments to Title 16 Section 1746 – Emergency Contraception Protocol [45-day comment period: Jan. 6-Feb. 20, 2012]

3. Board Approved - Undergoing Initial 45-Day Comment Period (Information Only)

Proposed Amendments to Title 16 starting at Section 1735.1 Related to Compounding Drug Products [45-day comment period: March 9 – April 23, 2012]

Regulation Hearing Scheduled for May 1, 2012 – 1:30 p.m.

4. Board Approved – Awaiting Notice (Information Only)

- a. Proposed Addition of Section 1762 – Additional Grounds for Unprofessional Conduct
- b. Proposed Addition of Section 1769 – Addition of Application Review to Criteria for Rehabilitation
- c. Proposed Amendment of Title 16 Section 1745 – Partial Fill of Schedule II Controlled Substance

5. Proposed Regulations Being Discussed By Committees (Not for Action - Update Only)

- a. Licensing Committee
 - Updates to the USP Standards Reference Manual
 - Standards for Agencies that Accredite Licensed Sterile Injectable Compounding Pharmacies
 - Continuing Education
 - Accreditation Agencies for Continuing Education
 - Self-Assessment of a Veterinary Food-Animal Drug Retailer
- b. Enforcement Committee
 - Requirements for Unique ID Numbers for Rx / E-Pedigree
 - Development of “Grandfathering” Provisions for Non-Pedigree Dangerous Drugs
- c. Communication and Public Education Committee
 - Notice to Consumers Posters / Video Display Format Option / Interpreter Availability

C. LEGISLATION AND REGULATION COMMITTEE

Third Quarterly Report on the Committee’s Goals for 2011/12